CDKN1B and cancer: Moreover, SKP2 has established proteolytic targets such as P27 and Cyclin E1 [16,17,28,41], which are oncogenes frequently amplified at the level of the genome in many cancers [29,30,31], including ~20% and ~23% of CRC cases, respectively [31].